Two members of U.S. FDA advisory panel resign over Alzheimer's drug approval
Two members of a panel of outside advisors to the U.S. Food and Drug Administration have resigned in protest at the agency's decision to approve Biogen Inc's (BIIB.O) Aduhelm for treatment of Alzheimer's disease despite the committee’s recommendation against doing so.
A sign marks a Biogen facility in Cambridge, Massachusetts, U.S. January 26, 2017. REUTERS/Brian SnyderTwo members of a panel of outside advisors to the U.S. Food and Drug Administration have resigned in protest at the agency's decision to approve Biogen Inc's
(BIIB.O)Aduhelm for treatment of Alzheimer's disease despite the committee’s recommendation against doing so.Mayo Clinic neurologist Dr. David Knopman, a panel member who had been recused from the advisors’ November meeting to review the drug because he was an investigator in clinical trials of Biogen’s drug, said he resigned on Wednesday.
"I was very disappointed at how the advisory committee input was treated by the FDA," Dr. Knopman told Reuters. "I don't wish to be put in a position like this again.”The 11-member committee voted nearly unanimously in November that Biogen's drug should not be approved, citing inconclusive evidence that the drug was effective. Due to his recusal, Knopman did not participate in the vote. headtopics.com
The FDA on Monday gave the drug "accelerated approval,” based on evidence that it can reduce a likely contributor to Alzheimer’s, rather than proof of a clear benefit against the disease.On Tuesday, a member of the advisory group who voted against the approval, Washington University neurologist Dr. Joel Perlmutter, resigned from the committee, citing the FDA's approval of Aduhelm without further discussion with its advisors.
The FDA said it does not comment on matters related to individual members of advisory committees.Our Standards:More from ReutersSign up for our newsletterSubscribe for our daily curated newsletter to receive the latest exclusive Reuters coverage delivered to your inbox.Read more: Reuters Top News »
COVID-19 live updates: CDC says there won’t be any federal vaccine mandate
A pandemic of the novel coronavirus has now infected more than 195 million people worldwide and killed over 4.1 million of them.
newborn NotaryServices SpainNATO Navy_JAG AF JAG
Two doctors have resigned from a prestigious panel after FDA approved a controversial Alzheimer's drugBusiness Insider tells the global tech, finance, markets, media, healthcare, and strategy stories you want to know.
FDA Approves First New Alzheimer’s Drug in Nearly Two DecadesThe approval of the Biogen drug, which has the molecular name aducanumab and will be sold as Aduhelm, marked a watershed in Alzheimer’s drug research after billions of dollars in investment. but they forgot where they put it
WSJ News Exclusive | Mystery Buyer Pays $157.5 Million for Two Condos on New York’s Billionaires’ RowTwo condos at New York’s 220 Central Park South have sold for a combined $157.5 million. It is one of the city’s priciest residential transactions of all time. good A NUG leader admits to engaging in terrorist activities ￼ The best choice I've made this year was investing in cryptocurrency and forex trading and earning from home. With the help of micheal33590 I've been earning $ 23k weekly I've never regretted this decision. 🙏🏻🙏🏻
‘BuzzFeed Unsolved’ Final Two Seasons Set to Premiere This Year“BuzzFeed Unsolved,” the long-running online documentary series starring Shane Madej and Ryan Bergara, is coming to an end after five years. The eighth and final season of “BuzzFeed Uns… WHYYYYYYYYYYY It is literally carrying Buzzfeed so hard why would they end it. Final season whyy ?
18 Reasons Why You Should Binge-Watch 'Love, Victor' Before Season Two BeginsCan I say just because it’s amazing? lenif18
Two Men, a Highway Robbery, and One Hot Encounter'Percy licked into Kit’s mouth, and that was when Kit realized he wasn’t in charge of this kiss, not in the slightest.'